Fulgent Genetics shareholders approve 2026 equity plan authorizing 2M new shares

Fulgent Genetics, Inc.

2026 Equity Incentive Plan replaces prior 2016 plan; authorizes 2,000,000 new shares plus up to 1,500,000 from forfeited awards.
All four director nominees elected: Ming Hsieh, Linda Dong, Michael Nohaile, Regina Groves (each to serve until 2027 annual meeting).
Ratification of Deloitte & Touche LLP as independent auditor for fiscal year 2026 approved (24.5M for, 87K against).
Non-binding advisory vote on named executive officer compensation passed (19.8M for, 2.4M against, 45K abstain).

item 5.02item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.